EMEA-000145-PIP02-12-M04

Table of contents

Key facts

Invented name
  • Xgeva
  • Prolia
Active substance
denosumab
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/0213/2021
PIP number
EMEA-000145-PIP02-12-M04
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of osteoporosis
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Amgen Europe B.V. 

E-mail: medinfointernational@amgen.com
Tel. +44 (0)1223 420305

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating
Average
1 rating